Respiratory Diseases Stocks List Ranked for 2024 |

Respiratory Diseases ETFs
Recent Respiratory Diseases News

Symbol	Grade	Name	% Change
ALVO	B	Alvotech	1.97
AZN	A	Astrazeneca PLC	0.53
EHAB	F	Enhabit, Inc.	-2.13
GILD	F	Gilead Sciences, Inc.	-1.12
MRK	A	Merck & Company, Inc.	-0.69
REVB	F	Revelation Biosciences, Inc.	-0.60
SMLR	F	Semler Scientific, Inc.	-4.06
SPRY	C	ARS Pharmaceuticals, Inc.	1.16
SVRA	D	Savara, Inc.	-0.65
TBPH	F	Theravance Biopharma, Inc.	-6.12

View As Page of Charts

Related ETFs - A few ETFs which own one or more of the above listed Respiratory Diseases stocks.

Symbol	Grade	Name	Weight
PPH	B	Market Vectors Pharmaceutical ETF	11.82
MEDX	F	Horizon Kinetics Medical ETF	9.77
FTXH	D	First Trust Nasdaq Pharmaceuticals ETF	7.61
XLV	B	SPDR Select Sector Fund - Health Care	6.19
PJP	B	PowerShares Dynamic Pharmaceuticals	6.0

View all Respiratory Diseases ETFs...

Compare ETFs

Compare FTXH to PJP Compare MEDX to FTXH Compare PPH to FTXH

Respiratory Diseases Stocks Recent News

Date	Stock	Title
May 1	SMLR	Semler Scientific: Not Perfect But Worth Considering
Apr 30	AZN	Novo, Teva, AstraZeneca issued FTC warnings over ‘bogus’ patents
Apr 30	GILD	Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
Apr 30	ALVO	Alvotech to produce Humira biosimilar for Cigna's Quallent
Apr 30	AZN	AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
Apr 30	SPRY	ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
Apr 30	MRK	Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Apr 30	SMLR	Semler Scientific, Inc. (NASDAQ:SMLR) is largely controlled by institutional shareholders who own 52% of the company
Apr 30	ALVO	U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
Apr 29	AZN	AstraZeneca Admits Its COVID-19 Vaccine May Cause Blood Clotting Side Effect In Very Rare Case, But Causal Mechanism Unknown
Apr 29	AZN	AstraZeneca’s Fasenra: Approval for asthma may initiate COPD approval
Apr 29	AZN	AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement
Apr 29	MRK	Merck late-stage data strengthens profile of pneumonia vaccine candidate
Apr 29	MRK	Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
Apr 29	AZN	AstraZeneca's Enhertu buoyed by progression-free survival data in breast cancer
Apr 29	AZN	AstraZeneca, Daiichi look to broaden Enhertu use again with new study data
Apr 29	AZN	ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
Apr 29	GILD	Gilead expands FDA label for Biktarvy with Phase I pregnant HIV patient data
Apr 29	TBPH	Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024
Apr 29	AZN	Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week

Respiratory Diseases: Respiratory diseases are a group of conditions that affect the lungs and airways. These diseases can range from mild to severe and can include asthma, COPD, pneumonia, and lung cancer. Symptoms of respiratory diseases can include difficulty breathing, coughing, wheezing, and chest pain. Treatment for respiratory diseases can include medications, lifestyle changes, and surgery.

Browse All Tags